The CD34 cell surface antigen is a glycoprotein expressed by hematopoietic stem and progenitor cells and also by certain nonhematopoietic cell-types. Because CD34 expression is regulated both at the transcriptional and the posttranscriptional level, we attempted t o identify factors that, by interacting with the 5' flanking region of the human CD34 gene, may regulate its promoter activity in proliferating hematopoietic cells. By electrophoretic mobility shift assay, UV cross-linking and DNase I footprinting analyses, we identified a multiprotein complex, designated NC3A. that specifically interacts with the CD34 promoter region from nucleotides -375 t o -351. Sequence analysis of this region revealed the presence of a distinct motif, TCATTT. Chloramphenicol acetyl-transferase assays used t o assess promoter activity in transiently transfected cells showed that this TCA-HE CD34 ANTIGEN is a cell surface glycoprotein T which defines a subset of hematopoietic progenitor cells with self-renewal capacity and the ability to reconstitute hematopoiesis in irradiated primates and marrow ablated humans.'.* Beside normal bone marrow (BM) cells, 30% of blasts from acute leukemia patients express CD34 antigen.' In addition, CD34 is present in a subset of BM stromal cells: and in the small vessel endothelium.5 In the mouse, CD34 expression was also detected in brain, testis, embryonic tibroblasts, and fetal
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The function of CD34 is not yet clear; however, the reported interaction of L-selectin with CD34 in endothelial cells' suggests that, in the marrow, it may mediate the interaction between hematopoietic stem cells and marrow stromal lectins,'" perhaps functioning as a signal or facilitating the binding of locally released growth factors: In this regard, studies on thymocytes of transgenic mice expressing the human CD34 antigen indicate that CD34 promotes the interaction of hematopoietic cells with the BM stroma.13 Two studies assessing the phenotype of CD34 knock-out mice revealed a reduction in eosinophilic accumulation in the lung after allergen-inhalation," and a decreased ability of marrow and spleen-derived hema-llT-containing element, which is conserved in both the human and the murine CD34 genes, mediates positive regulatory activity in hematopoietic and nonhematopoietic cells, and acts as an enhancer when placed upstream of a heterologous promoter. Moreover, loss of CD34 promoter activity was caused by mutation of the T C A T motif. In addition, the interaction of the nuclear multiprotein complex NCJA with this enhancer element is proliferation-dependent. These data indicate that, although not cell-type specific, the formation of a multiprotein complex NC3A interacting with the region from nucleotides -375 t o -351 plays an important role in controlling CD34 promoter activity in proliferating hematopoietic cells. 0 1996 by The American Society of Hematology.
topoietic progenitors to expand in liquid cultures in response to hematopoietic growth factors. I 5 Moreover, overexpression of the full length, but not a truncated, CD34 cDNA prevents interleukin-6 (IL-6)-induced differentiation of M 1 myeloid leukemic cells,'6 suggesting that CD34 downregulation is required for hematopoietic differentiation. The mechanisms responsible for switching on-off CD34 expression in hematopoietic cells are still not well-defined, though there is evidence for both transcriptional and posttranscriptional regulation."." The stage-and tissue-specific expression of CD34 might be influenced by chromatin structure'"."'; however, distinct regions of the CD34 promoter involved in transcription regulation have been identified by activation of reporter gene expression, in both CD34 positive and negative cells.l'~*' Moreover, specific transcription factors such as cmyb, ets-2, and MZFl appear to act as positive or negative regulators of CD34 expression by direct interaction with binding sites in the 5' flanking region of the CD34
To dissect tissue-specific mechanisms of transcription regulation in hematopoietic cells, we investigated DNA-protein interactions in the CD34 5' flanking region and assessed the significance of such interactions for promoter activity in hematopoietic and nonhematopoietic cells. We report here the identification of several nuclear factors that, although not tissue specific, act in a DNA binding, proliferation-dependent manner to regulate the promoter activity of the human CD34 gene.
gene.'2-2s

MATERIALS AND METHODS
Cell Cultures and Primary Cells
TK-tsl3 Syrian hamster fibroblasts (a kind gift of Dr R. Basergd, Thomas Jefferson University, Philadelphia, PA), are thymidine kinase-deficient cells derived from ts13 cells?6 and were maintained at 34°C in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal calf serum (FCS), and 2 mmol/L glutamine (GIBCO, Grand Island, NY).
The T98G human glioblastoma cell line (a kind gift of Dr W.E. Mercer, Thomas Jefferson University, Philadelphia, PA) was maintained in culture as described.*' For synchronization purposes, T98G cells were plated at high density (80% confluency) and maintained in culture for 5 days in 0.1 % heat-inactivated FCS. Cells were then replated at lower density, stimulated to proliferate with 10% FCS and collected after 14, 18, 20, 22, 24, 26 , and 28 hours. For cell cycle analysis, 5 X lo5 cells were fixed in 70% ethanol for 15 minutes at 4"C, washed, and incubated in 1 mL phosphate-buffered saline (PBS) containing 0.1% Nonidet P-40 (NP-40) and 1 pg/mL DNase-free RNase A (Boehringer Mannheim, Indianapolis, IN) for 10 minutes at room temperature. Propidium iodide (5 mglmL) was added, and cells were analyzed by flow cytometry (EPICS Profile Analyzer; Coulter Corp, Hialeah, FL).
The KG-I myeloblastic and the U937 monocytic leukemia cell lines (American Type Culture Collection, Rockville, MD) were grown at 37°C in RPMI-1640 medium supplemented with 10% FCS and 2 mmol/L L-glutamine (GIBCO). Macrophage differentiation of KG-1 and U937 cells was induced by treatment with phorbol myristate acetate (PMA) (20 ng/mL) and ionomycin (0.16 pg/mL), or PMA (20 ng/mL) alone, respectively. Exponentially growing KG-1 and U937 cells, PMNionomycin-treated KG-I cells, and PMAtreated U937 cells were harvested and incubated (30 minutes on ice), in PBS containing 0.1% gelatin, 0.01% sodium azide, 5% human serum, and monoclonal antibodies to CD71 (transferrin receptor) (5E9) and to C D l l b (B43.4). Cells were washed twice, incubated (30 minutes on ice) with fluorescein isothiocyanate-conjugated goat antimouse Ig F(ab')*, and analyzed by flow-cytometry on a EPICS Profile Analyzer (Coulter Corp).
Peripheral blood lymphocytes (PBL) were obtained by density gradient centrifugation on FicolVHypaque (FM) (Lymphoprep, Nycomed Pharma AS, Oslo, Norway). Phytohemagglutinin (PHA) blasts were obtained after a 5-day culture of PBL (5 X los cells/mL) in the presence of 0.5 mglmL PHA (PHA-M, Wellcome Diagnostic, Dartford, UK). Cells were incubated in a humidified 5% COz atmosphere at 37°C and periodically counted.
Plasmids
A fragment of the CD34 promoter region (nucleotides -666 +234)'7.21 was obtained by polymerase chain reaction (PCR) amplification of human placental genomic DNA and by cloning the amplified segment into the pCRII vector (Invitrogen Corp, San Diego, CA). This segment was then subcloned in pBlueScript SK+ (pBS-CD34-15), digested with HindIII and BamHI restriction enzymes, and then subcloned into the HindIII and BumHI sites of the CAT vector pBLCAT3.'* pBL-CD34CAT plasmid was digested with HindIII and Xho I restriction enzymes and the CD34 fragment was subcloned into the HindIIUSaZ I sites of pCAT-basic vector (Promega, Madison, WI).
The plasmid pBS-CD34-15 was digested with Xho I and Cla I restriction enzymes to remove an Acc I site contained in the polylinker. Plasmid pBS-Acc I-CD34-15 was then digested with Hpu I and Acc I restriction enzymes, gel-purified, and religated. The BamHUHindIII fragment (A3A) lacking the Hpa IAcc I segment of the CD34 promoter was then subcloned into pBLCAT3 vector previously digested with BamHUHindIII restriction enzymes.
This plasmid was prepared following HindIIUSal I restriction enzymes digestion of pBL-CD34-A3ACAT, and subcloning the purified fragment into HindIIIISul I-digested pCAT-basic vector.
A PCR fragment containing the human CD34 promoter region from nucleotide -375 to nucleotide -26617.*' was phosphorylated by polynucleotide kinase and subcloned (in the sense and in the antisense orientation) in front of the Herpes simplex virus pBL-CD34CAT. pUC-CD34CAT.
pBL-CD34-A3ACAT.
pUC-CD34-A3ACAT.
pTK-CD34-3CAT.
(HSV) thymidine kinase (TK) minimal promoter contained in the pTK-CAT vector.2q
A PCR fragment containing the human CD34 promoter region from nucleotide -460 to nucleotide -340,17.21 carrying the mutation of the TCATTT element (nucleotides -366 to -361) into GAACAG, was digested with Acc IlHpa I restriction endonucleases and subcloned into pBS-Acc I-CD34-15 digested with the same restriction enzymes to remove the wild-type sequence. The mutated full-length CD34 promoter was then excised from the vector by BamHUHindIII restriction enzymes digestion and subcloned into the pBLCAT-3 vector, previously digested with BamHUHindIII restriction enzymes.
Constructs were automatically sequenced using the Taq Dye Deoxy Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, CA).
pBL-CD34-TCAll7mutCAT.
Nuclear Protein PuriJication and Electrophoretic Mobility Shqt Assay (EMSA)
To prepare nuclear extracts, lo7 cells were collected, washed twice in phosphate-buffered saline (PBS), and then resuspended in 1 mL of a buffer containing 10 mmolL HEPES pH 7.9, 1 mmolL EDTA, 60 mmoVL KCI, 1 mmol/L dithiothreitol (DTT), in the presence of protease inhibitors (1 mmoVL phenylmethylsulfonylfluoride [PMSF]), 2 pg/mL aprotinin, 2 pg/mL leupeptin, and 1 pg/mL pepstatin A). Deionized NP-40 was added to the cell suspension at a final concentration of 0.1% vollvol and cells were disrupted using a Dounce homogenizer (B-type pestle). The nuclear pellet was resuspended in 100 pL of 20 mmol/L HEPES pH 7.9,0.4 mol/L NaC1,25% glycerol, 1 mmolL EDTA in the presence of protease inhibitors, and nuclear proteins were obtained by three rounds of freezing in dry-icefit-OH and thawing at 37°C; lysates were clarified and the amount of protein was quantitated by Bradford assay (Bio-Rad, Richmond, VA). Whole cell extracts were prepared as de~cribed.~' Twelve micrograms of nuclear extracts or 20 pg of total extracts were used for EMSA. Lysates in binding buffer (10 mmol/L Tris-HC1 pH 7.5, 50 mmoVL NaCl, 1 mmolL EDTA, 10% glycerol, and 1 mmol/L dithiothreitol) were incubated with 0.12 mg/mL of poly (dI-dC) for 10 minutes on ice. y-[32P]-end-labeled double-stranded oligodeoxynucleotide or DNA probes (5 X IO4 cpm) were added to the binding reactions, which were incubated for an additional 15 minutes at room temperature. When indicated, EMSA were performed in the presence of a 100-fold molar excess of double stranded DNA fragments used as specific or nonspecific competitors. Binding reactions were electrophoresed in nondenaturing 5% polyacrylamide gel electrophoresis (PAGE) in low ionic stringency conditions (0.25X Tris borate EDTA). Gels were dried and exposed to x-ray films for autoradiograAgents that disrupt protein-protein interactions were used in EMSA as described," with some modifications. Specifically: (1) sodium deoxycholate (DOC), was added (0.2% to I S % ) , at the end of the binding reaction, and the samples were incubated on ice for an additional 20 minutes, before loading onto the native 5% PAGE; (2) formamide, at a final concentration of 30% or 20% (vol/vol), was added to the nuclear extracts and, after 20 minutes on ice, diluted 1:4 by adding the binding mixture to the formamide-treated extracts. Binding reactions were then performed as described above.
were used in EMSA either as probes or as competitors: CD34-3 (nucleotides -375 to -266), CD34-3A (nucleotides -375 to -351), CD34-3B (nucleotides -355 to -325), CD34-3C (nucleotides -329 to -295), CD34-3D (nucleotides -297 to -266), 3AL (nucleotides -368 to -349), 3AR (nucleotides -372 to -353) and 3AS (nucleotides -386 to -367); TCATTTmut (nucleotides -375 to -351), in phy.
The following fragments of the human CD34 which the bases AAATGA (nucleotides -366 to -361) were mutated to GAACAG; the 35 mer double-stranded oligodeoxynucleotide (5'-ggggtccccccttactggactcaggttgccccctg-3') was used as nonspecific competitor (n.s.c. or n.s.p.).
UV Cross-Linking Analysis
CD34-3 and CD34-3A fragments were 'ZP-labeled, using [a3']-PdATP, [a'*]PdCTP and BrdUTP as base-substitute, or by endlabeling, respectively. EMSA binding reactions, performed as described above, were fractionated on a native 5% PAGE, which was subsequently exposed to ultraviolet irradiation (250 d) using a Stratalinker (Stratagene, La Jolla, CA). A gel-slice containing the shifted complexes was soaked in 1 X Laemmli buffer for 15 minutes, and overlaid on a 8.5% sodium dodecyl sulfate-PAGE (SDS-PAGE). The 2D-gel was dried and exposed to x-ray films for autoradiography.
DNase I Footprinting Analysis
The in vitro DNase I protection assay was performed as described,'? with some modifications. Briefly, binding reactions were performed using 30 pg of nuclear extracts and 20,000 cpm of a single-stranded-'2P-end-labeled PCR fragment. DNase I (Boehringer Mannheim Co) digestion was performed on ice for 5 minutes by addition of a 2 p L solution containing different dilutions of DNase I (0.1 to 1 U) in the presence of 60 mmol/L MgClz. Reactions were stopped by addition of one volume of 1% sodium dodecyl sulfate (SDS), 20 mmol/L EDTA pH 8.0, 200 pg/mL proteinase K (Sigma, St Louis, MO), 1 mg/mL tRNA, and incubation at 65°C for 20 minutes. The samples were phenol-chloroform-extracted, ethanol precipitated, washed with 80% ET-OH, dried, resuspended in formamide loading buffer, heat-denatured, and loaded onto 8% polyacrylamide-8M urea gel. Gels were dried and exposed to x-ray film for autoradiography. Maxam and Gilbert G+A reactions of the same DNA fragments were used as a marker.
Southwestern Blotting
Equal numbers (1.5 X loh) of cells were harvested, washed twice with ice-cold PBS and lysed in 75 p L Hepes Buffer (10 mmol/L HEPES pH 7.5, 1. 50 mmol/L NaCI, 10% glycerol, 1 m m o l n EDTA, I mmol/L DTT) containing 0.5% NP-40 in the presence of protease inhibitors used at the indicated concentrations (1 mmol/L PMSF, I0 pg/mL leupeptin, 25 pg/mL aprotinin, 100 pg/mL pepstatin, I mmoll L benzamidine). After 20 minutes on ice, total lysates were frozen in dry-ice, thawed at 37°C and clarified. The lysates in 1 X Laemmli buffer were fractionated by 8.5% SDS-PAGE, and transferred onto nitrocellulose membrane (Schleicher and Schuell, Keene, NH). Southwestern analysis was performed as described?' with some modifications. After blotting, proteins were denatured in binding buffer (10 mmol/L Tris-HCI pH 7.5, 50 mmol/L NaCI, I mmol/L EDTA, I mmol/L DTT, 10% glycerol) supplemented with 6 mol/L guanidine hydrochloride and renatured by several washings, by which the guanidine hydrochloride was progressively diluted. Free membrane sites were saturated at room temperature for 30 minutes in binding buffer containing 5% fat-free dry-milk. Filters were exposed to the "P-labeled DNA probe ( 10' cpm/mL) at room temperature for 2 hours in binding buffer containing 0.25% dry-milk and 5 pg/mL sonicated salmon sperm DNA. The filters were washed with binding buffer 4 times (7 minutes each), blotted briefly on 3MM paper, and exposed to x-ray film at -80°C for 7 days for autoradiography.
CAT Assays
TK-tsl3 hamster fibroblasts were plated at a concentration of 10' cells/plate, grown for 16 to 18 hours and transfected, by calciumphosphate pre~ipitation,~~ with 15 pg of the indicated plasmids. KG-1 cells were split to 105/mL and transiently transfected 24 hours later as described.'5 Briefly: 1 day after plating, cells were washed twice with FCS-and L-glutamine-free RPMI-1640, resuspended in the same medium (1.4 X IO7 cells1500 pL) and electroporated (Gene Pulser; Bio-Rad: 960 pF to 300 V) with 35 pg of reporter plasmids and 5 pg of the plasmid containing the bacterial 0-galactosidase gene driven by the SV40 early promoter, used as internal control for transfection efficiency. After electroporation, cells were incubated for 5 minutes on ice and transferred to 10 mL RPMI-1640 containing 10% FCS plus 2 mmol/L L-glutamine. Cells were harvested 48 hours after transfection. Proteins were extracted in hypotonic buffer by freeze-thawing and normalized for transfection efticiency using the P-galactosidase assay, as suggested by the manufacturer (Promega). Cellular lysates were incubated with ['"Clchloramphenicol and acetyl-CoA (90 minutes) at 37°C. CAT levels were assayed by thin-layer chromatography followed by autoradiography and the percentage of acetylated [ I4C] chloramphenicol was determined by scintillation counting.
Nuclear Run-on Transcription Assag
Nuclear run-on was performed as described by Chan After 20 minutes at 26"C, newly synthesized RNA were extracted using the APGE-method (acid-phenolguanidium-extraction), isopropanol-precipitated in the presence of 10 pg/mL tRNA and purified onto a G-50 RNase-free Sephadex spin column (Boehringer Mannheim). Equal numbers of counts of nascent radiolabeled transcripts were hybridized to a nitrocellulose membrane (Schleicher and Schuell), containing 10 pg each of the indicated plasmid, spotted using a slot-blot apparatus (Hoefer, San Francisco, CA). Hybridizations were performed for 72 hours at 42°C in 50% formamide, 5 x saline sodium citrate buffer (SSC). I X Denhardt's solution, 50 mmol/L Na,PO, buffer, 100 pg/mL salmon sperm DNA. 0. I % SDS. Membranes were washed in 2 X SSC/O. 1% SDS (twice at room temperature and once at 37°C 20 minutes each), followed by a single wash in 0.1 x SSC/0. I8 SDS (20 minutes. 65°C). Autoradiography was performed at -70°C for 5 days with intensifying screens. Densitometry measurement was performed using a personal densitometer (Molecular Dynamics. Inc, Sunnyvale. CA). Probes used for nuclear run-on studies included a -I .5 kb Xbu I fragment of the human CD34 cDNA containing the complete coding region in pBluescript vector (pBSXbn ICD34). The 28s rRNA sequence served as positive ~o n t r o l , '~ whereas the Bluescript vector (Stratagene) served as control for nonspecific hybridization.
RESULTS
The CD34 Promoter Region From Nucleotides -375 to -351 Interacts With Nuclear Proteins Expressed in CD34' KG-1 Myeloblastic Leukemia Cells But Not in CD34 Peripheral Blood Resting L.vmphocyte.7
Six different segments of a 650 bp CD34 promoter sequence (Fig IA) were amplified by PCR from plasmid pBSK-CD34prom-152' and tested in EMSA for their ability to bind proteins in nuclear extracts from the CD34* myeloblastic leukemia cell line KG-I, or from resting PBL. A retarded complex was detected in KG-I, but not in PBL nuclear extracts, when the fragment CD34-3 (nucleotides -375 to -266) was used as probe (Fig 1 B) . No differences were observed in EMSA with probes CD34-I, CD34-2, CD34-4, CD34-5, and CD34-6 (data not shown). To define more precisely the segment of the CD34-3 fragment responsible for the shifted complex, four different and partially overlapping double-stranded oligodeoxynucleotides (CD34-3A. -3B. -3C. and -3D) (Fig IA) were used in EMSA with nuclear extracts from KG-I cells and PBL. Only the 25-mer CD34-3A probe (nucleotides -375 to -35 I ) interacted specifically with KG-I nuclear proteins, and formed a complex designated Nuclear Complex-3A (NC-3A) (Fig IC) . The formation of this complex was inhibited by a 100-fold molar excess of cold CD34-3A fragment (Fig IC. lane 3) . but not of a nonrelated double-stranded oligodeoxynucleotide (Fig IC. lane 4) , or of fragments CD34-3B. -3C. and -3D (Fig ID) . These data indicate that a protein or different proteins expressed in KG-I cells but not in PBL specifically recognize a consensus sequence (from nucleotides -375 to -35 I ) in the CD34 promoter region. Sequence analysis of the CD34-3A segment revealed the presence of a motif, TCATIT, highly homologous to the consensus sequence nCATTT/A present in the granulocyte-macrophage colony stimulating factor (GM-CSF). IL-5. and IL-4 promoters.'X32
Cliciracteri-rrtion of the NC-3A Binding Site by EMSA and DNrrse I hi Vitro Footprinting To determine which nucleotides were involved in the formation of the NC-3A complex, three different doublestranded ODNs (3AS. 3AL. and 3AR). partially overlapping and contained within the CD34-3A fragment (Fig 2A) . were used as competitors in EMSA with KG-I nuclear extracts and the CD34-3 (Fig 2B) or the CD34-3A fragment (Fig  2C) as probes. NC-3A complex formation was inhibited by a 100-fold molar excess of 3AR or 3AL. but not of the 3AS double-stranded ODN (Fig 2B and C, lanes 2 to 4) . EMSAs were also performed using the 3AS. 3AR, and 3AL double- 
stranded ODNs as probes. The DNA fragments 3AL and 3AR. but not 3AS. were able to shift a band with mobility similar to that of the NC-3A complex (data not shown). Moreover. NC-3A complex formation was not inhibited by a 100-fold molar excess of the CD34-3A fragment mutated in the bases from -366 to -361 (TCATTTmut) (Fig 2B and  C. lane 5) . Together. these results indicate that the CD34 promoter region from nucleotide -37 I to nucleotide -352 
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(S'-AGCCAAAATGAATACTTATA-3') represents the core of the binding site for the protein(s) forming the NC-3A complex. To confirm that this sequence was responsible for NC-3A complex formation, DNase I footprinting assays were performed using KG-1 nuclear extracts and the CD34-3 fragment as probe. Only one region from nucleotide -368 to nucleotide -354, included in the CD34-3A promoter sequence, was protected from DNase I digestion (Fig 2D) . The specificity of the interaction was confirmed by adding to the reaction a 100-fold molar excess of CD34-3A. Use of this competitor resulted in loss of protection over a region extending from nucleotide -368 to -354 (-CAAAATGAA-TACTTA-) (Fig 2E, lane 3) . Addition of an unrelated 25 mer double-stranded ODN to the binding reaction did not affect DNase I activity (Fig 2E, lane 2) .
The CD34-3A Pronioter Region From Nitcleoticie -375 to Nicclroriiie -351 Acts as an Enhancer Element
Functional analyses were performed using CAT reporter constructs containing the full-length CD34 promoter region (pBL-CD34CAT and pUC-CD34CAT) or a deletion mutant lacking the CD34-3A binding region (pBL-CD34A3ACAT and pUC-CD34A3ACAT). CD34-expressing hematopoietic cells (KG-I) or CD34 nonexpressing cells (Tk-tsl3 and T98G) were transiently transfected either with the plasmid carrying the full-length CD34 promoter (Fig 3A, B , and C, (Fig 3A. B, and C, lane 4) . The deletion in the CD34 promoter (from nucleotide -449 to nucleotide -345) included the CD34-3A region and resulted in about 6-to IO-fold decrease in CAT activity (Fig 3, lane  4) . indicating that elements contained in this region are important for CD34' transcriptional regulation. Plasmids pBL-CAT3 or pCAT-basic and pRSVCAT were used as negative and positive controls, respectively. To exclude the possibility that CD34 sequences upstream of the oligomer CD34-3A (nucleotides -375 to -351) bind other factors and are responsible for the increase in transactivation, two fragments, including or not the CD34-3A region, were used as probes in EMSA. No KG-I proteins bound to the CD34 promoter region (nucleotides -449 to -375); in contrast, a band corresponding to the NC-3A complex was detected with the -449 to -346 "P-labeled CD34 fragment (data not shown). To determine whether the -375 to -266 CD34 promoter region acts as an enhancer, we inserted it upstream of the HSV thymidine kinase promoter-CAT construct and assessed its activity by CAT assays in transiently transfected Tk ts13 cells. As expected, this region had a strong enhancer effect (four to fivefold increase) on the expression of the CAT gene (Fig 3D, lane 4) : also, the enhancer activity was DNA orientation independent (data not shown). The promoter sequence (nucleotides -368 to -3S4), which was protected from DNase I digestion (Fig 2D) . includes the TCATTT box (nucleotides -366 to -361) shown to be involved in the regulation of several cytokine promoters.2X-'" Accordingly, a construct (pBL-CD34-TCATTTmutCAT) in which the TCATTT motif is replaced by the sequence CTGTTC was used in CAT assays to determine whether the enhancer activity exhibited by the -375 to -266 CD34 promoter region depends on the integrity of the TCATTT element. In comparison to the wild-type CD34 promoter, mutation in the TCA-TTT motif resulted in a five to sixfold decrease in CAT activity (Fig 3E, lanes 3 and 4) .
Cliarncteriiarion ?f the Nirclenr Proteiri(s) Irirdved in rlie NC-3A Comp1e.r Fonnnriori
The possibility that multiple proteins were involved in NC-3A complex formation was analyzed by EMSA performed in the presence of DOC or formamide used as dissociating agents. The NC-3A complex formed with KG-I nuclear extracts and "P-labeled CD34-3 DNA fragment appeared to be resistant either to sodium deoxycholate concentrations that disrupt protein-protein interactions (0.2% to 0.8% vol/vol), or to formamide treatment ( 2 0 9 to 3 0 9 vol/ vol) (Fig 4A) . The absence of binding in the presence of 1.5% DOC indicates that, at this concentration. this agent disrupts the DNA-protein interaction. The results of these experiments suggest that a complex of multiple proteins in which only one protein interacts with DNA is not involved in the binding with CD34-3 fragment, but do not exclude that multiple polypeptides might bind to the same DNA segment. EMSA followed by UV-cross-linking analysis was subsequently performed with KG-I nuclear extracts and CD34-3 or CD34-3A fragment as probe. The mobility shift pattern. obtained using CD34-3 fragment as probe, revealed, in addition to the NC-3A complex, the presence of three other minor complexes (C2, C3, and C4) (Fig 4B) . The upper band seen in EMSA with the probe CD34-3A contains a single cross-linked species, with an apparent molecular weight of 180 kD (data not shown), corresponding to the cross-linked NC-3A complex shifted by the probe CD34-3 ( Fig 4B) . After UV cross-linking, the three other complexes (C2, C3, and C4) were resolved in 2D SDS-PAGE into three different bands with apparent molecular weights of 96, 50, and 29 kD, respectively (calculated after deducting the molecular weight of the probe) (Fig 4B) . Although four different complexes (NC-3A. C2. C3, and C4) were resolved, the nature of the NC-3A complex is still not clear. To determine if the NC-3A complex formation is due to the interaction of CD34-3 with a single protein of approximately 180 kD or with several different proteins, Southwestern analyses were performed on total lysates prepared from hematopoietic (KG-I, HL60, and PBL) and nonhematopoietic (T98G and TK-ts 13) cells, using the "P-labeled CD34-3 fragment as probe. This region specifically interacts with three different proteins with apparent molecular weights of 96, SO, and 29 kD (Fig 4C) . No protein of -180 kD was detected in the different lysates, suggesting that the NC-3A complex could be formed following the direct interaction of these three different proteins with DNA. In agreement with the EMSA results shown above. the CD34-3 probe did not recognize any protein in the PBL lysate. Similar results were obtained in Southwestern analysis using CD34-3A fragment as probe (not shown).
NC--?A Biticling Activie Diirinsg Cell Proliferatioti citicl Differetttiotioti
To assess whether NC-3A complex formation is cell type specific or is specific. in hematopoietic cells, for a defined stage of differentiation. total lysates of hematopoietic (KG-1. HL60. KS62. U937. THP-I. Jurkat, Daudi. RPMI 8866, PBL, and activated NK cells) and nonhematopoietic (TK-tsl3, T98G, and COS7) cells were used in EMSA with the "P-labeled CD34-3 fragment. A shifted complex corresponding to NC-3A was detected in all cell lysates, with the exception of PBL (Fig 5) . These results clearly indicate that the presence of NC-3A complex is not hematopoietic cellspecific. Because resting PBL were the only negative cells and the cells positive for the presence of the NC-3A complex were all proliferating, resting PBL were stimulated for 5 days with PHA and EMSAs were performed using total lysates of PBL and PHA-blasts obtained from the same donor. Proteins present in the PHA-blasts lysate formed a complex with the CD34-3 fragment (Fig 6. lane 3 ) comigrating with the KG-I nuclear complex N C 3 A (Fig 6. lane I) . As expected. no complexes were detected in the lysate from resting PBL (Fig 6, lane 2) . The specificity of the complex present in the mitogen-activated PBL lysate was shown by use of a 100-fold molar excess of CD34-3A double stranded oligodeoxynucleotide, as competitor (Fig 6, lane 4) . To further investigate whether the binding activity of the proteins forming the NC-3A complex is strictly dependent on the proliferation status of the cells. T98G glioblastoma cells were plated at high density (80% confluency) and maintained in culture for 5 days in 0.1% heat-inactivated FCS. Cells were then stimulated to proliferate with 10% FCS, collected at 14, 18, 20, 22, 24, 26, and 28 hours and, used either to determine DNA content by flow cytometry (Fig 7A) . or to prepare total lysates for gel shift assays with the CD34-3 fragment as probe (Fig 7B) . A complex comigrating with the KG-1 NC-3A was detected in cell lysates from proliferating (Fig 7B. lane I) , but not from serum-starved T98G cells T98G cell extracts ( Fig 7B, lane 2) . NC-3A complex formation, barely detectable in cells in GO (Fig 7B and C, lane 2) , peaked in the G1 phase (Fig 7B and C, lane 3) , and remained at approximately constant. although lower, levels in the S, G2, and M phases (Fig 7B and C, lane 4 to 9) . To assess whether formation of the NC-3A complex was influenced by differentiation, the myeloid KG-I and U937 cell lines, which represent myeloblast and monocyte stages of differentiation. respectively, were induced to differentiate to macrophages by treatment with PMA (U937) or PMA/ionomycin (KG-I). After 2 (U937) or 3 to 5 (KG-I) days of treatment with PMA (20 ng/mL) or PMA (20 ng/mL)/ionomycin (0.16 pg/mL), both cell lines ceased proliferating. as determined by their DNA content measured by propidium-iodide staining (Fig 8B) . Compared to untreated cells, immunofluorescence analyses of PMAhonomycin-treated KG-1 and PMA-treated U937 cells revealed a decrease in transfemn receptor and an increase in CDI 1 b expression (Fig 8C) , a phenotype associated with cell maturation. To determine if NC-3A complex formation is regulated during terminal differentiation of hematopoietic cells, total lysates from control. PMA/ionomycininduced KGI cells, and PMA-induced U937 cells were used in EMSA with the CD34-3 fragment as probe. A marked decrease in the abundance of the NC-3A complex was observed in both PMA-treated U937 cells and in PMA/ionomycin-treated KGI cells (Fig 8A) . Moreover, to assess whether the downregulation of the NC-3A complex observed in KG-1 cells induced to differentiate into monocyte/macrophages correlates with a decrease in CD34 transcription rate, nuclear run-on assays were performed in both proliferating and 3 to 5 days PMA (20 ng/mL)/ ionomycin (0.16 pg/ mL)-treated KG-1 cells. CD34 transcription, detectable in proliferating KG-1 cells, was significantly reduced (2.5-to 5-fold. respectively) in PMA/ionomycin-treated KG-1 cells (Fig 8D) . No changes were detected in the hybridization to the Bluescript vector or the 28s ribosomal sequence, used as negative and positive control, respectively.
DISCUSSION
In the hematopoietic system, CD34 expression is restricted to a subset of cells with self-renewal capacity and the ability to reconstitute all hematopoietic lineages.'.'.'" Although different transcription factors"." (ie, c-myb, ets2, and MZFl ) can modulate CD34 expression, it is still not clear whether the primary mode of regulation occurs at a transcriptional or posttranscriptional level."-" The goal of the present study was to identify factors that can transcriptionally regulate CD34 gene expression in CD34' hematopoietic cells.
EMSA was used, initially, to identify elements that might bind selectively to proteins obtained from CD34' myeloblastic cells (KG-I), but not from CD34-PBL. A KG-I complex, NC-3A, was found to specifically interact with a CD34 promoter region from nucleotide -375 to nucleotide -266. Further analyses of this region revealed that the DNA segment involved in the interaction is included in the region from nucleotide -375 to nucleotide -35 1. Transient transfection experiments in hematopoietic and nonhematopoietic cells to compare the transcriptional activity of the wild type CD34 promoter with that of a deletion construct lacking the CD34-3A region. indicate that efficient transcriptional stimulation of the CD34 promoter depends on the presence of this 25 bp segment (Fig 2) . Moreover, using a heterologous promoter (TK promoter), we showed that this region functions as an enhancer in TK-tsl3 hamster fibroblasts. In this regard, Burn et al" showed that a construct containing the CD34 promoter region from nucleotide -390 to nucleotide -175. which includes the CD34-3A region (nucleotides -375 to -35 I), was positively regulated in both hematopoietic and nonhematopoietic cells, in comparison to a construct lacking this promoter region.
The sequence of the region from nucleotide -375 to nucleotide -35 l (-GGACAGCCAAAATGAATACTTATAT-) revealed that it contains a distinct motif, TCATTT, highly related to the consensus sequence nCATTT/A, previously identified in GM-CSF, IL-5, and 1L-4
In these cytokine promoters, this conserved element is more proximal (from -61 to -38) than that identified in the CD34promoter. However, these cytokine promoters all contain a canonical TATA box, whereas the CD34 promoter is TATA-less, suggesting that these common elements might serve similar functions, assuming that multiple transcription initiation sites exist in the CD34 promoter.
The CD34 promoter (nucleotides -390 to + 175) includes several potential stem-loop regions similar to that located between the translation and the transcription initiation sites that appear to regulate the murine CD34 promoter in a positive fashion.43 Loop(s) formation could juxtapose the TCATTT motif with sites of transcription initiation. DNase I footprinting assays identified a 16 bp protected region (nucleotides -368 to -354), which includes the TCATTT box and its downstream sequences, and could serve as a core recognition site for cellular transcription factors. In support of these findings, deletion or mutation of the CD34-3A promoter region to alter the TCATTT motif abolished NC-3A binding, and the mutant double stranded oligomer did not compete in EMSA with the wild type sequence. Moreover, mutation of the TCATTT element in the CD34 promoter (nucleotides -366 to -361) results in a marked decrease in CAT activity, indicating that the integrity of the TCATTT motif is necessary for CD34 promoter activity. In agreement with our results, several reports have indicated that different nuclear factors interact with the motif nCATTT/A contained in the GM-CSF, IL-5, and IL-4 promoters, and that the integrity of this motif is necessary for promoter activity.38-42.44 Furthermore, the nCATIT/A element contained in the IL-5 promoter, exhibited enhancer activity when linked to both human interferon-y and TK minimal promoters."' The related sequence of the human GM-CSF promoter, by itself, did not have enhancer activityM; however, its integrity and that of its adjacent regions were critical for both enhancer function and mitogen inducibility of the GM-CSF prom~t e r .~~ In KG-I cells, at least three or four different proteins have been identified that bind the CD34 promoter region containing the TCA'ITT motif (CD34-3A). UV cross-linking experiments indicated that the less abundant complexes C2,C3, and C 4 are formed by three proteins with apparent molecular weights of 96, 50, and 29 kD, respectively. Despite the absence of protein-protein interactions detectable in EMSA in the presence of dissociating agents, the NC-3A complex might result from the interaction between the three proteins of 96, 50, and 29 kD and their specific recognition sequences (where the TCATTT motif plays a critical role), rather than from specific binding of a single 180 kD protein to its binding site. This hypothesis is supported by the results of EMSA with different probes (CD34-3 or CD34-3A), or Southwestern analyses performed with total extracts from both hematopoietic and nonhematopoietic cells. The CD34-3 fragment was able to shift a single complex (NC-3A) of -180 kD specificaily competed only by the CD34-3A. However, when assayed in Southwestern, it bound to three different proteins with apparent molecular weights corresponding to C2 (96 kD), C3 (SO kD), and C 4 (29 kD), but not to a protein with higher molecular weight, even after long exposure. In addition, experiments directed to purify the NC-3A complex, using a two-step purification method (gel shift followed by oligo-dT column) revealed the presence of three proteins with molecular weights corresponding to those mentioned above (data not shown). No interaction was detected between probe CD34-3 and the PBL proteins, confirming the absence of binding observed in EMSA. The capacity of the enhancer region containing the TCATTT motif to bind different proteins is not unprecedented. The IL-4 and GM-CSF promoter regions containing the TCATTT motif can bind in EMSA to several proteins with apparent molecular weights of 97 kD, 65 kD, and 50 kD or > 100 kD, 96 kD, 55 kD, 50 kD, and 29 kD, respectively.'x-'' Recent evidence suggests that the CATT motif of the human GM-CSF promoter interacts with, and is positively regulated by, an AP-1 and an Spl-related complex." In contrast, the third complex involves the YY 1 nuclear factor and appears to regulate GM-CSF promoter activity negatively.lS Supershift assays with antibodies specific to the AP-I and SP-I transcription factors did not alter the mobility of either NC-3A or C2, C3, and C4 complexes. However, the antibody specific to human YY 1 protein inhibited formation of the C3 complex (data not shown), but it is yet unknown whether YY I is involved in the regulation of the CD34 promoter.
The presence of NC-3A was not restricted to a particular cell-type, as EMSA performed using extracts from hematopoietic and nonhematopoietic cells revealed the presence of il complex comigrating with NC-3A (Fig 5) .
The formation of the NC-3A complex correlated with the proliferative status of the cells, as it was induced in PHAstimulated human PBL (Fig 61, and destabilized in PMA/ ionomycin-treated KG-1 and PMA-treated U9.37 cells (Fig  8) . Because KG-I and U937 cells represent two different stages of myeloid differentiation (myeloblastic and monocytic, respectively), the absence of the NC-3A complex in PMAhonomycin-treated KG-1 and PMA-treated U937 cells likely reflects the block of cell proliferation rather than the induction of myeloid terminal differentiation. In agreement with these findings, the NC-3A complex was absent in serum-starved T98G cells, but was induced in T98G cells stimulated to re-enter the cell cycle (Fig 7) . The observation of Fraser et al" that the proteins interacting with the TCATTT region of the GM-CSF promoter mediate the mitogen inducibility of this promoter, and form more stable complexes in PHA-stimulated T lymphocytes than in resting cells, is consistent with our data. Moreover, Naora et al" showed that the induction of NF-IL-SA and NF-GM-CSFA (two proteins that recognize the TCATTT motif within the IL-5 and the GM-CSF promoters) correlates with the induction of cell proliferation in ConA-stimulated T lymphocytes. The decrease in the abundance of the NC3A complex during PMAhonomycin-induced KGI differentiation correlated with a reduction in CD34 transcription rate, as indicated by the results of nuclear run-on assays (Fig 8) . It has been previously reported that the expression of the CD34 gene is not regulated at the transcriptional level in KGl cells induced to differentiate, as nuclear run-on assays did not show changes in the rate of CD34 transcription measured 24 hours after treatment with PMA and ionomycin." These observations are not in contrast with our results because, after 24 hours of PMNionomycin treatment, markers of macrophage differentiation only begin to be upregulated and the proliferation of KGl cells is not completely arrested. In agreement with this phenotype, NC-3A complex levels were essentially identical to those detected in proliferating KGl cells (data not shown).
In summary, we have shown that the proliferation-dependent protein complex NC-SA is involved in positive regulation of the CD34 promoter via binding to its recognition site which carries the core motif TCATTT. The tissue and stagespecific regulation of CD34 expression is likely mediated by specific transcription factors acting in the context of a chromatin structure enabling such interaction. 1y, 20 Accordingly, the proliferation-dependent NC3A complex might be a component of the transcription machinery, perhaps necessary to enhance CD34 transcription rate in proliferating progenitor cells, and whose downregulation might be required to extinguish CD34 expression during progenitor cell differentiation. Experiments to address this hypothesis are now in progress.
